WHEREAS the American Academy of Family Physicians (AAFP) supports a woman's access to reproductive and maternity health services and opposes non evidence-based restrictions on medical care and the provision of such services (2014 COD),

WHEREAS early pregnancy loss is the most common complication of early pregnancy, affecting 10-20 percent of all clinically recognized pregnancies, with most occurring before 12 weeks gestation, 1-2

WHEREAS patients consider many factors when choosing between miscarriage management options, and they report higher levels of satisfaction of their care when treated according to their preferences 3.

WHEREAS a recent high quality randomized-controlled trial demonstrated that a single dose of mifepristone prior to misoprostol is superior to misoprostol alone for medical management of early pregnancy loss without increasing the rate of serious adverse events,4

WHEREAS Women receiving mifepristone had lower rates of uterine aspiration required for treatment failure than women receiving misoprostol alone and completion of their medication abortion was therefore more timely and cost-effective, 5-6

WHEREAS the American College of Obstetricians and Gynecologists updated their protocol for medical management of early pregnancy loss in November of 2018 to recommend that “a dose of mifepristone (200mg orally) before misoprostol administration should be considered when mifepristone is available” as the standard of care for medical management of EPL and supports improving access to mifepristone for reproductive health indications, including for medical management of early pregnancy loss 7.

WHEREAS the current US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) and Elements to Assure Safe Use (ETASU) requirements of mifepristone limit access to mifepristone by making it difficult for providers to purchase and prescribe the medication for office based treatments.

WHEREAS in 2018 the American Academy of Family Physicians resolved to endorse the principle that the REMS classification on mifepristone is not evidence based and resolved to engage in advocacy and lobbying efforts to overturn the REMS classification on mifepristone to improve access to reproductive health care, 8

WHEREAS the American Family Physician current guidelines and education on management of early pregnancy loss do not include the use of mifepristone for medical management 9.
RESOLVED, that the CAFP will instruct its delegates to submit a resolution to the AAFP to support the safety and efficacy of mifepristone as the most evidence-based care for medical management of EPL.

RESOLVED, that the CAFP will instruct its delegates to submit a resolution to the AAFP to reaffirm its efforts to overturn restrictions on the prescribing of Mifepristone, especially in light of data supporting its use in early pregnancy loss.

RESOLVED, that the CAFP will instruct its delegates to submit a resolution to the AAFP to recommend that early pregnancy loss management be included in the FMX and American Family Physician topics on a rotational basis.

Citations:


